Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vermillion Taps McLain for CEO

Premium

Vermillion has appointed Thomas McLain as president and CEO. He replaces Bruce Huebner, who has served as interim CEO since last November when he took over for Gail Page.

Huebner will remain a director of the company.

Prior to joining Vermillion, McLain served as CEO and CFO of Claro Scientific. Before that, he held senior management positions at Nabi Biopharmaceuticals (now Biota Pharmaceuticals) and Bausch & Lomb. He has also served on the boards of Eastman Chemical, and the Biotechnology Industry Organization.

He holds an MBA in accounting and information systems from the University of Rochester, Simon Graduate School of Business, and a BA in economics from the College of the Holy Cross.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.